Alzheimer’s Test Launch And 2026 Outlook Might Change The Case For Investing In Labcorp (LH)

Simply Wall St.02-19

In February 2026, Labcorp Holdings reported fourth-quarter 2025 sales of US$3,515.8 million and full-year sales of US$13.95 billion, alongside higher net income and earnings per share from continuing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612107472?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","is_english":true,"pubTime":"2026-02-19 13:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612107472","market":"sg","top_or_hot":-1,"title":"Alzheimer’s Test Launch And 2026 Outlook Might Change The Case For Investing In Labcorp (LH)","media":"Simply Wall St.","content":"<div>\n<p>In February 2026, Labcorp Holdings reported fourth-quarter 2025 sales of US$3,515.8 million and full-year sales of US$13.95 billion, alongside higher net income and earnings per share from continuing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/alzheimers-test-launch-and-2026-outlook-might-change-the-cas\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alzheimer’s Test Launch And 2026 Outlook Might Change The Case For Investing In Labcorp (LH)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlzheimer’s Test Launch And 2026 Outlook Might Change The Case For Investing In Labcorp (LH)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-19 13:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/alzheimers-test-launch-and-2026-outlook-might-change-the-cas><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In February 2026, Labcorp Holdings reported fourth-quarter 2025 sales of US$3,515.8 million and full-year sales of US$13.95 billion, alongside higher net income and earnings per share from continuing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/alzheimers-test-launch-and-2026-outlook-might-change-the-cas\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0742534661.SGD","symbol_name":"Fidelity America A-SGD (hedged)","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/alzheimers-test-launch-and-2026-outlook-might-change-the-cas","article_id":"2612107472","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/alzheimers-test-launch-and-2026-outlook-might-change-the-cas","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612107472","pubTimestamp":1771479495,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In February 2026, Labcorp Holdings reported fourth-quarter 2025 sales of US$3,515.8 million and full-year sales of US$13.95 billion, alongside higher net income and earnings per share from continuing operations year over year, while issuing 2026 revenue guidance of US$14.61 billion to US$14.79 billion.\nThe company also completed a multi-year US$3.64 billion share repurchase program and expanded its Alzheimer’s testing portfolio with the nationwide launch of the FDA-cleared Elecsys pTau-181...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0742534661.SGD":"Fidelity America A-SGD (hedged)","AI":"C3.ai, Inc.","BK4551":"寇图资本持仓","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LH":"徕博科","BK4587":"ChatGPT概念","BK4528":"SaaS概念","BK4588":"碎股","BK4550":"红杉资本持仓","BK4196":"保健护理服务","BK4023":"应用软件","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4543":"AI"},"translate_title":"阿尔茨海默病测试的启动和2026年展望可能会改变投资Labcorp(LH)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AI":0.82,"LH":1.5},"content_text":"In February 2026, Labcorp Holdings reported fourth-quarter 2025 sales of US$3,515.8 million and full-year sales of US$13.95 billion, alongside higher net income and earnings per share from continuing operations year over year, while issuing 2026 revenue guidance of US$14.61 billion to US$14.79 billion. The company also completed a multi-year US$3.64 billion share repurchase program and expanded its Alzheimer’s testing portfolio with the nationwide launch of the FDA-cleared Elecsys pTau-181 blood test, underscoring an emphasis on higher-value diagnostics and capital returns. Now we’ll assess how Labcorp’s 2026 guidance and new FDA-cleared Alzheimer’s blood test reshape its longer-term investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementLabcorp Holdings Investment Narrative RecapTo own Labcorp Holdings, you need to believe it can keep growing core diagnostics and biopharma lab services while protecting margins despite reimbursement, regulatory and competitive pressures. The new 2026 guidance and Alzheimer’s blood test do not materially change the near term focus on execution in Diagnostics, while PAMA and broader pricing pressures remain the key risks to watch. The most relevant recent development is Labcorp’s nationwide launch of the FDA cleared Elecsys pTau-181 Alzheimer’s blood test, which directly supports its push into higher value neurology diagnostics. This kind of innovation aligns with the existing catalyst of expanding specialized test offerings, potentially reinforcing Labcorp’s position with health systems and biopharma partners if adoption holds up. Yet while innovation is attractive, investors should also be aware that potential PAMA related reimbursement cuts could... Read the full narrative on Labcorp Holdings (it's free!)Labcorp Holdings' narrative projects $15.6 billion revenue and $1.3 billion earnings by 2028. This requires 5.1% yearly revenue growth and about a $536.6 million earnings increase from $763.4 million today.Uncover how Labcorp Holdings' forecasts yield a $300.18 fair value, a 8% upside to its current price.Exploring Other PerspectivesLH 1-Year Stock Price Chart Four fair value estimates from the Simply Wall St Community span roughly US$200 to US$391 per share, reflecting very different views on Labcorp’s upside. Against that backdrop, the company’s focus on higher value tests like Elecsys pTau-181 could be a key factor shaping how its growth potential and risks are weighed by different investors.Explore 4 other fair value estimates on Labcorp Holdings - why the stock might be worth 28% less than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Labcorp Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Labcorp Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Labcorp Holdings' overall financial health at a glance.Searching For A Fresh Perspective?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:Find 53 companies with promising cash flow potential yet trading below their fair value.The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612107472","isCrawlerRequest":true}